Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish.
Victoria PattersonFarid UllahLaura BryantJohn N GriffinAlpa SidhuSheila SaligananMackenzie BlaileMargarita Sifuentes SaenzRosemarie SmithSara EllingwoodDorothy K GrangeXuyun HuMaimaiti MireguliYanfei LuoYiping ShenMaureen S MulhernElaine ZackaiAlyssa L RitterKosaki IzumiJulia HoefeleMatias WagnerKorbinian Maria RiedhammerBarbara SeitzNathaniel H RobinDana GoodloeCyril MignotBoris KerenHelen CoxJoanna JarvisMaja HempelCynthia Forster GibsonFrédéric Tran Mau ThemAntonio VitobelloAnge-Line BruelArthur SorlinSarju G MehtaF Lucy RaymondKelly GilmoreBradford C PowellKaren E WeckChumei LiAnneke T Vulto-van SilfhoutThea GiacominiMaria Margherita MancardiAndrea AccogliVincenzo SalpietroFederico ZaraNeeta L VoraErica E DavisRebecca D BurdineElizabeth Joyce BhojPublished in: Science advances (2023)
We report 21 families displaying neurodevelopmental differences and multiple congenital anomalies while bearing a series of rare variants in mitogen-activated protein kinase kinase kinase kinase 4 ( MAP4K4 ). MAP4K4 has been implicated in many signaling pathways including c-Jun N-terminal and RAS kinases and is currently under investigation as a druggable target for multiple disorders. Using several zebrafish models, we demonstrate that these human variants are either loss-of-function or dominant-negative alleles and show that decreasing Map4k4 activity causes developmental defects. Furthermore, MAP4K4 can restrain hyperactive RAS signaling in early embryonic stages. Together, our data demonstrate that MAP4K4 negatively regulates RAS signaling in the early embryo and that variants identified in affected humans abrogate its function, establishing MAP4K4 as a causal locus for individuals with syndromic neurodevelopmental differences.